OICHARTS
8 AMThe 8 AM report →

OTLK

Outlook Therapeutics, Inc. Common Stock · XNAS · 131 sessions on record
$0.57▼ −0.05 · −8.3%from $0.63 the session before · Sep 30, 2026 close · end of day
Open
$0.63
High
$0.63
Low
$0.57
Day's range
$0.069.9% of the previous close
VWAP
$0.59close −3.3% from it
Volume, shares
9.01M2.16× the 20-session average
Traded, $
$5.3M
Trades
22K410 shares per trade
Previous close
$0.63−0.05 to the close
Market cap
$139.6Mat the close of Sep 30
Day range1% of the way up
$0.57$0.63
52-week range23% of the way up
$0.18 Apr 7$1.88 Jun 22

−69% from the high · +220% from the low

Options

No listed options on OTLK

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
OTLK close over the last 126 sessions, with S&P 500 rebased to the first close0.201.021.83axis spans 812%S&P 500OTLKApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 812 percent.

Quarterly results

consolidated · latest filed Aug 18, 2026 · SEC filings

Profit −$20.3M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of OTLK on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 18——−$20.3M—-0.15▼ −1.4%S&P 500 +0.2% · −1.6 pp
Mar 2026filed Aug 18——−$4.5M—-0.05▼ −1.4%S&P 500 +0.2% · −1.6 pp
Dec 2025filed Aug 18——−$23.1M▼ −230%-0.38▼ −1.4%S&P 500 +0.2% · −1.6 pp
Sep 2025filed Dec 19——−$13.3M▼ −330%-0.46—not reached
Jun 2025filed Aug 18$1.5M—−$20.2M▼ −150%-0.55▼ −1.4%S&P 500 +0.2% · −1.6 pp
Mar 2025filed Aug 18——−$46.4M—-1.50▼ −1.4%S&P 500 +0.2% · −1.6 pp
Dec 2024filed Aug 18——$17.4M—0.72▼ −1.4%S&P 500 +0.2% · −1.6 pp
Sep 2024filed Dec 27——$5.7M—5.70—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of OTLK on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Sep 2025$1.4M—−$62.4M—-1.79
FY24to Sep 2024——−$75.4M—-4.06
FY23to Sep 2023——−$59.0M—-4.72
FY22to Sep 2022——−$66.1M—-0.31
FY21to Sep 2021——−$53.2M—-0.35

Fundamentals

consolidated · filings to Jun 2026 · close $0.57 on Sep 30

market cap $139.6M.

Valuation
Market cap
$139.6Mon Sep 30
Price to earnings
—
Trailing EPS
$-1.04diluted · consolidated · four quarters to Jun 2026
Price to book
—
Book value a share
—
Debt to equity
—
Return on equity
—
Dividend yield
—
Price to sales
—
Shares outstanding
243Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$61.1Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap
Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
MRNAModerna, Inc. Common Stock$76.88Bon Sep 30—11$192.57
HALOHalozyme Therapeutics, Inc.$12.53Bon Sep 3032consolidated87$110.40
TECHBio-Techne Corp.$11.36Bon Sep 3062consolidated5.4$72.47
KODKodiak Sciences Inc Common Stock$5.96Bon Sep 30—98$94.80
ALLOAllogene Therapeutics, Inc. Common Stock$552.8Mon Sep 30—1.3$1.60
DTILPrecision BioSciences, Inc. Common Stock$172.8Mon Sep 30—3.8$6.26
OTLKOutlook Therapeutics, Inc. Common Stock$139.6Mon Sep 30——$0.57
BSEMBioStem Technologies, Inc. Common Stock$55.2Mon Sep 30—2.0$3.09
TVGNTevogen Inc. Common Stock$43.1Mon Sep 30——$6.62
BCDABioCardia, Inc. Common Stock$15.3Mon Sep 30—5.7$1.01

Shareholding

SEC Forms 3, 4 and 5

No open-market insider buying or selling in the last 90 days.

Insider tradesSEC Forms 3, 4 and 5 · the latest 6
OTLK insider trades
InsiderTradeSharesPriceHeld after
Haddadin Yezan MuntherDirectorbought · Jun 2, 202629,000$0.8366,167
GMS Ventures & InvestmentsDirector,TenPercentOwnerbought · May 28, 20268,539,709$0.5922,092,068
HILZINGER KURT JDirectorbought · May 26, 2026400,000$0.44423,655
THURMAN RANDY HDirectorbought · May 26, 20265,000$0.435,593
Haddadin Yezan MuntherDirectorbought · May 26, 202634,000$0.4437,167
Sukhtian Faisal GhiathDirectorbought · May 27, 2026122,174$0.41125,574

Corporate actions

exchange records

No corporate action on record for OTLK yet.

Price history

131 sessions on record · to Sep 30 · end of day

OTLK is −8.0% over 20 sessions against the S&P 500's +0.1%, 69% below its 52-week high, realised volatility 57% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $OTLK %S&P 500 %Difference pp
120 sessionssince Apr 9$0.22▲ +160%▲ +12%+150
60 sessionssince Jul 7$1.46▼ −61%▲ +2.0%−63
20 sessionssince Sep 1$0.62▼ −8.0%▲ +0.11%−8.1
5 sessionssince Sep 23$0.66▼ −13%▼ −0.67%−13
1 sessionsince Sep 29$0.63▼ −8.3%▼ −0.21%−8.1
Averages of the closeclose against each average
5-session average
$0.62close −7.5% from it
20-session average
$0.65close −12% from it
50-session average
$0.80close −28% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.047.5% of the close
Average day's range, 20
$0.046.4% of the close
Volume against 20 sessions
2.16×9.01M vs 4.44M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
57%≈ ±3.6% a session · moved more than that on 7 of 20
Realised volatility, 60
120%≈ ±7.4% a session · moved more than that on 11 of 60
Beta to S&P 500, 60
0.27moved with S&P 500 on 33 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
11 up · 9 downof 20
Last 60 sessions
25 up · 35 downof 60
Best session, 250
▲ +46%May 27
Worst session, 250
▼ −24%Jul 27

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 62% of reported volume on Sep 30, 2026, against 61% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
OTLK daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 20263.27M5.25M62.2%
Sep 29, 20261.8M2.92M61.9%
Sep 28, 20262.22M4.18M53.3%
Sep 25, 2026914K2.07M44.1%
Sep 24, 20261.06M1.75M60.7%
Sep 23, 20261.04M1.82M57.1%
Sep 22, 2026976K1.71M57.0%
Sep 21, 2026814K1.58M51.6%
Sep 18, 20261.23M1.81M68.3%
Sep 17, 2026904K1.64M55.0%

Filings

SEC EDGAR · newest first
OTLK SEC filings
FiledFormReport date
Sep 30, 20268-KSep 25, 2026
Sep 18, 20268-KSep 16, 2026
Sep 2, 20264Sep 1, 2026
Sep 2, 20263Sep 1, 2026
Aug 27, 20268-KAug 23, 2026
Aug 19, 2026SCHEDULE 13G—
Aug 18, 202610-QJun 30, 2026
Aug 17, 2026NT 10-QJun 30, 2026
Aug 14, 20264Aug 14, 2026
Aug 14, 20264Aug 14, 2026
Aug 14, 20268-KAug 12, 2026
Aug 14, 2026424B5—
Aug 14, 20268-KAug 14, 2026
Aug 14, 2026SCHEDULE 13D/A—
Aug 14, 20264Aug 12, 2026
Aug 12, 2026424B5—
Aug 12, 20268-KAug 12, 2026
Jul 29, 20264Jul 29, 2026
Jul 24, 20268-KJul 24, 2026
Jul 24, 20268-KJul 21, 2026
Jul 23, 20264Jul 21, 2026
Jul 23, 20264Jul 21, 2026
Jul 21, 2026EFFECT—
Jul 21, 2026424B3—
Jul 17, 2026S-3—

About Outlook Therapeutics, Inc. Common Stock

SEC and exchange records
Company
Outlook Therapeutics, Inc. Common Stock
Exchange
XNAS
Industry
Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK
1649989
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:42 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.